IOVA - Iovance Biotherapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
9.68
-0.23 (-2.32%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close9.91
Open9.79
Bid8.75 x 800
Ask10.88 x 4000
Day's Range9.62 - 10.36
52 Week Range7.85 - 19.90
Volume954,188
Avg. Volume1,525,615
Market Cap1.192B
Beta (3Y Monthly)3.46
PE Ratio (TTM)N/A
EPS (TTM)-1.36
Earnings DateMar 11, 2019 - Mar 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.33
Trade prices are not sourced from all markets
  • TheStreet.com2 days ago

    Here's a Handful of Small Biotechs Where Insiders Are Buying

    The market has acted a bit better so far this week on some signs trade tensions between the United States and China might be lessening a hair. Quotient shares have had a decent year despite what has been a challenging year in this space but have pulled back from their highs this summer. Quotient's stock receives little analyst coverage in the States despite a market cap of around $400 million.

  • Is Iovance Biotherapeutics, Inc. (IOVA) A Good Stock To Buy?
    Insider Monkey4 days ago

    Is Iovance Biotherapeutics, Inc. (IOVA) A Good Stock To Buy?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]

  • Benzinga6 days ago

    Insider Buys Of The Week: Iovance, Mohawk, United Continental

    Conventional wisdom says insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. Iovance Biotherapeutics Inc (NASDAQ: IOVA) saw a director adding to his stake this past week. This San Carlos, California-based clinical-stage biotechnology company focuses on cancer immunotherapy products.

  • What Kind Of Shareholders Own Iovance Biotherapeutics Inc (NASDAQ:IOVA)?
    Simply Wall St.11 days ago

    What Kind Of Shareholders Own Iovance Biotherapeutics Inc (NASDAQ:IOVA)?

    Every investor in Iovance Biotherapeutics Inc (NASDAQ:IOVA) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often Read More...

  • GlobeNewswirelast month

    Iovance Biotherapeutics to Participate at November Investor Conferences

    SAN CARLOS, Calif., Nov. 13, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating.

  • Associated Presslast month

    Iovance Biotherapeutics: 3Q Earnings Snapshot

    On a per-share basis, the San Carlos, California-based company said it had a loss of 36 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

  • GlobeNewswirelast month

    Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    Iovance Biotherapeutics, Inc. (IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its third quarter 2018 financial results and provided a corporate update. Following our recent end of Phase 2 meeting with the FDA, we released information about the meeting outcome and our US registration path, receipt of RMAT designation for metastatic melanoma, an abbreviated set of our latest clinical data, and conducted a successful round of financing. The company is now in a very strong financial position which will allow us to pursue our registration program to commercialize our TIL therapy,” said Dr. Maria Fardis, Ph.D., MBA, president and chief executive officer of Iovance Biotherapeutics.

  • GlobeNewswirelast month

    Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

    Iovance Biotherapeutics, Inc. (IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that a presentation of new data from the ongoing Phase 2 lifileucel metastatic melanoma trial (C-144-01) will occur at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C. from November 7-11, 2018. Dr. Amod Sarnaik, from H. Lee Moffitt Cancer Center, the lead investigator in the C-144-01 study, will discuss the new data as an oral presentation on Sunday, November 11, 2018.  These results will also be presented as a poster beginning November 9, 2018.  The company will also host a live webcast of its melanoma program at an event for analysts and investors on Friday, November 9, 2018 from 6:30 – 8:30pm ET during the SITC meeting.

  • Nantahala Capital Management’s Returns, AUM, and Holdings
    Insider Monkeylast month

    Nantahala Capital Management’s Returns, AUM, and Holdings

    Nantahala Capital Management is a New Haven-based hedge fund founded in 2004 by 26-year-old Wilmot Harkey. He named his firm after the river in the Smoky Mountains which he visited with his family when he was a kid, as he wanted a name that would remind him of his background. Although, Wil Harkey was very young […]

  • GlobeNewswire2 months ago

    Iovance Biotherapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Tuesday, November 6, 2018

    SAN CARLOS, Calif., Oct. 30, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating.

  • GlobeNewswire2 months ago

    Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe

    Iovance Biotherapeutics, Inc. (IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, and MaSTherCell S.A., a subsidiary of Orgenesis Inc. (ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO), today announced that the two companies have entered into a new three-year Manufacturing Services Agreement. MaSTherCell will manufacture TIL for Iovance’s European late-stage clinical trials in its commercial-ready cGMP manufacturing suites.

  • GlobeNewswire2 months ago

    Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering

    Iovance Biotherapeutics, Inc. (IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the closing of an underwritten public offering of 25,300,000 shares of its common stock at a public offering price of $9.97 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are approximately $252.2 million.  The shares of common stock issued and sold in the offering include 3,300,000 shares issued upon the exercise in full by the underwriter of its option to purchase additional shares at the public offering price, less the underwriting discounts and commissions.

  • Why Iovance Biotherapeutics, Inc. Is Sinking Today
    Motley Fool2 months ago

    Why Iovance Biotherapeutics, Inc. Is Sinking Today

    Recent gains, which didn't make much sense to begin with, were very short-lived.

  • Why Canopy Growth, SSR Mining, and Iovance Biotherapeutics Jumped Today
    Motley Fool2 months ago

    Why Canopy Growth, SSR Mining, and Iovance Biotherapeutics Jumped Today

    Find out which of these stocks had the best gains.

  • GlobeNewswire2 months ago

    Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock

    Iovance Biotherapeutics, Inc. (IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the pricing of an underwritten public offering of 22,000,000 shares of its common stock at a public offering price of $9.97 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be $219.3 million.  In addition, Iovance has granted the underwriters a 30-day option to purchase up to 3,300,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions.

  • Benzinga2 months ago

    The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

    Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical device companies made it to 52-week highs. Down In The Dumps (Biotech stocks ...

  • GlobeNewswire2 months ago

    Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

    Iovance Biotherapeutics, Inc. (IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Iovance intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, less the underwriting discounts and commissions.

  • GlobeNewswire2 months ago

    Iovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Company’s Clinical Program

    —FDA acknowledged acceptability of a single-arm cohort for registration in metastatic melanoma post PD-1 blocking antibody and, if BRAF mutation positive, a BRAF inhibitor or.

  • GlobeNewswire3 months ago

    Iovance Biotherapeutics to Present at the 2018 Cantor Global Healthcare Conference

    SAN CARLOS, Calif., Sept. 26, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...

  • ACCESSWIRE3 months ago

    Immuno Oncology & Targeted Therapy Companies Set to Breakout

    HENDERSON, NV / ACCESSWIRE / September 12, 2018 / Immuno Oncology has been getting investors revved up in 2018. Abpro and Neon announced IPOs and recently, German biotech Affimed agreed to an alliance with Roche's Genentech to discover new cancer immunotherapies with an amazing $5 billion dollar deal. Roche is not the only major player in Immuno Oncology, and you can bet their competition is working to make their own splash announcements in the coming months.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Arrowhead Pharmaceuticals and Iovance Biotherapeutics

    NEW YORK, NY / ACCESSWIRE / September 7, 2018 / Arrowhead Pharmaceuticals exploded on positive data results on Thursday while shares of Iovance Biotherapeutics were deep in the red on its own concerning ...

  • Investor's Business Daily3 months ago

    Biotech Dives After Experimental Lung Cancer Regimen Disappoints

    Iovance Biotherapeutics stock toppled by double digits Thursday after a third of patients who received its experimental lung cancer regimen worsened following treatment.

  • Why Iovance Biotherapeutics Stock Is Crashing Today
    Motley Fool3 months ago

    Why Iovance Biotherapeutics Stock Is Crashing Today

    A key clinical update sent Iovance's shares spiraling downward today.

  • Are Options Traders Betting on a Big Move in Lion Biotechnologies (IOVA) Stock?
    Zacks3 months ago

    Are Options Traders Betting on a Big Move in Lion Biotechnologies (IOVA) Stock?

    Investors need to pay close attention to Lion Biotechnologies (IOVA) stock based on the movements in the options market lately.